We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
From ribavirin to NAD analogues and back to ribavirin in search for anticancer agents.
- Authors
Pankiewicz, Krzysztof W.; Felczak, Krzysztof
- Abstract
Ribavirin, a broad-spectrum antiviral agent is used in the clinic alone or in combination with other antivirals and/or interferons. Numerous structural analogues of ribavirin have been developed, among them tiazofurin, which is inactive against viruses but is a potent anticancer drug. Tiazofurin was found to inhibit nicotinamide adenine dinucleotide (NAD)-dependent inosine monophosphate dehydrogenase (IMPDH) after metabolic conversion into tiazofurin adenine dinucleotide (TAD), which binds well but could not serve as IMPDH cofactor. TAD showed high selectivity against human IMPDH vs. other cellular dehydrogenases. Mycophenolic acid (MPA) was even more specific, binding at the cofactor-binding domain of IMPDH. Ribavirin adenine dinucleotide, however, did not show any significant inhibition at the enzymatic level. We synthesized numerous NAD analogues in which natural nicotinamide riboside was replaced by tiazofurin, MPA moiety, or benzamide riboside, and the adenosine moiety as well as the pyrophosphate linker were broadly modified. Some of these compounds were found to be low nanomolar inhibitors of the enzyme and sub-micromolar inhibitors of cancer cell line proliferation. The best were as potent as tyrosine kinase inhibitor gleevec heralded as a 'magic bullet' against chronic myelogenous leukemia. In recent years, ribavirin was rediscovered as a potential anticancer agent against number of tumors including leukemia. It was clearly established that its antitumor activity is related to the inhibition of an oncogene, the eukaryotic translation initiation factor (eIF4E).
- Subjects
ANTINEOPLASTIC agents; RIBAVIRIN; NAD (Coenzyme); TRANSLATION initiation factors (Biochemistry); IMP dehydrogenase; MYCOPHENOLIC acid; TIAZOFURIN; LEUKEMIA treatment
- Publication
Heterocyclic Communications, 2015, Vol 21, Issue 5, p249
- ISSN
0793-0283
- Publication type
Article
- DOI
10.1515/hc-2015-0133